These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 20230917)
1. Oral adjuvant activity for nasal influenza vaccines caused by combination of two trihydroxy fatty acid stereoisomers from the tuber of Pinellia ternata. Nagai T; Shimizu Y; Shirahata T; Sunazuka T; Kiyohara H; Omura S; Yamada H Int Immunopharmacol; 2010 Jun; 10(6):655-61. PubMed ID: 20230917 [TBL] [Abstract][Full Text] [Related]
2. Pinellic acid from the tuber of Pinellia ternata Breitenbach as an effective oral adjuvant for nasal influenza vaccine. Nagai T; Kiyohara H; Munakata K; Shirahata T; Sunazuka T; Harigaya Y; Yamada H Int Immunopharmacol; 2002 Jul; 2(8):1183-93. PubMed ID: 12349955 [TBL] [Abstract][Full Text] [Related]
3. Anti-allergic activity of a Kampo (Japanese herbal) medicine "Sho-seiryu-to (Xiao-Qing-Long-Tang)" on airway inflammation in a mouse model. Nagai T; Arai Y; Emori M; Nunome SY; Yabe T; Takeda T; Yamada H Int Immunopharmacol; 2004 Oct; 4(10-11):1353-65. PubMed ID: 15313433 [TBL] [Abstract][Full Text] [Related]
4. Total synthesis and adjuvant activity of all stereoisomers of pinellic acid. Shirahata T; Sunazuka T; Yoshida K; Yamamoto D; Harigaya Y; Nagai T; Kiyohara H; Yamada H; Kuwajima I; Omura S Bioorg Med Chem Lett; 2003 Mar; 13(5):937-41. PubMed ID: 12617925 [TBL] [Abstract][Full Text] [Related]
5. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232 [TBL] [Abstract][Full Text] [Related]
6. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356 [TBL] [Abstract][Full Text] [Related]
7. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590 [TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854 [TBL] [Abstract][Full Text] [Related]
9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
10. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802 [TBL] [Abstract][Full Text] [Related]
11. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654 [TBL] [Abstract][Full Text] [Related]
12. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. Ainai A; Ichinohe T; Tamura S; Kurata T; Sata T; Tashiro M; Hasegawa H J Med Virol; 2010 Mar; 82(3):476-84. PubMed ID: 20087927 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944 [TBL] [Abstract][Full Text] [Related]
15. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine. Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790 [TBL] [Abstract][Full Text] [Related]
16. In vivo antiinfluenza virus activity of Kampo medicine Sho-seiryu-to through mucosal immune system. Yamada H; Nagai T Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):185-92. PubMed ID: 9646280 [TBL] [Abstract][Full Text] [Related]
17. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010 [TBL] [Abstract][Full Text] [Related]
18. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. Arulanandam BP; O'Toole M; Metzger DW J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116 [TBL] [Abstract][Full Text] [Related]
19. In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "sho-seiryu-to"--stimulation of mucosal immune system and effect on allergic pulmonary inflammation model mice. Nagai T; Yamada H Immunopharmacol Immunotoxicol; 1998 May; 20(2):267-81. PubMed ID: 9653672 [TBL] [Abstract][Full Text] [Related]
20. In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "Sho-seiryu-to"--effects on aged mice, against subtypes of a viruses and B virus, and therapeutic effect. Nagai T; Urata M; Yamada H Immunopharmacol Immunotoxicol; 1996 May; 18(2):193-208. PubMed ID: 8771367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]